GWOXI Stem Cell Obtains INCI Name Certification!
GWOXI Stem Cell has successfully listed its human adipose mesenchymal stem cell exosomes in the U.S. Personal Care Products Council's (PCPC) International Cosmetic Ingredient Dictionary and Handbook, with the official name "Dulbecco's Phosphate Buffered Saline; Human Adipose Derived Mesenchymal Stem Cell Exosomes." This achievement makes it the first company in Taiwan to obtain this international certification for adipose stem cell exosomes, setting a significant milestone for the domestic exosome industry.
Exosome Sources and GWOXI’s Advantage
Exosome sources are diverse, with many products on the market derived from plant or animal cells. In contrast, GWOXI Stem Cell develops a pharmaceutical-grade cosmetic ingredient from a clinical-grade human adipose mesenchymal stem cell source, thereby applying new drug clinical technology to cosmetic applications. Compared to stem cells from other tissue sources, adipose stem cells are multipotent stem cells with the advantages of being easy to obtain, abundant in quantity, immunotolerant, and capable of inhibiting inflammation and promoting angiogenesis. They are already widely used in clinical research and regenerative medicine, with extensive scientific evidence to support their functionality, making them an ideal choice for the beauty and skincare industry.
The Regenerative Potential of Exosomes
Exosomes secreted by stem cells possess a nanoscale lipid bilayer outer membrane and are rich in growth factors, making them important messengers for regenerative information between cells. They have anti-inflammatory, antioxidant, and tissue repair acceleration capabilities. In skincare, they offer multiple benefits, including promoting collagen synthesis, anti-wrinkle effects, skin brightening, and skin repair. Numerous studies have also shown positive results for the application of stem cell exosomes on sensitive skin.
A New Milestone for GWOXI
GWOXI produces its exosomes from clinical-grade cell sources. In March 2025, the company's exosomes received international INCI Name certification following a review that confirmed their high purity, safety, and efficacy. This achievement officially grants GWOXI's exosomes a passport to the beauty and skincare market.
Market Trends and Regulations for Exosomes
In recent years, exosomes have become a hot topic, with applications advancing from academic and research institutions to clinical studies, and now also entering the beauty and skincare sector. According to data from Valuates Reports, the global exosome skincare market reached $570 million in 2022 and is projected to grow to $1.76 billion by 2028, with a high Compound Annual Growth Rate (CAGR) of 18.1%.
The booming market growth is accompanied by the establishment of regulations. Internationally, rules regarding the use of human-derived exosomes in beauty and skincare products remain relatively strict, with conditional approval granted only in Europe, the United States, Japan, South Korea, and Taiwan. All products still require evaluation and review before they can be marketed.
GWOXI's Strategy and Vision
As a pioneer in new stem cell drugs, GWOXI Stem Cell possesses over a hundred patented technologies and a clinical cell preparation facility. The company constantly pursues innovation and breakthroughs while actively expanding into overseas markets. It has established various cooperation models, including CDMO and OEM, to provide partners with diverse and flexible collaboration options.
As regenerative medicine becomes more common, its applications will not be confined to clinical medicine but will also permeate people's daily lives. The scope of cosmetics extends beyond our intuitive understanding of beauty and skincare products; it includes many daily necessities, from makeup and skincare to bath products, shampoos, conditioners, and even toothpaste. GWOXI Stem Cell integrates its professional regenerative medicine experience into daily life to benefit the public and works with global partners to advance the regenerative medicine industry.